Healthcare Services

Hypercholesterolemia Market Projected To Surpass $35.58 Billion By 2030 At 13.8% CAGR

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Hypercholesterolemia Market?

The hypercholesterolemia market has experienced rapid expansion in its size over recent years. Forecasts indicate that it will expand from $18.61 billion in 2025 to $21.24 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, this growth has been driven by factors such as the increasing prevalence of cardiovascular diseases, the extensive adoption of statins as initial treatment, a rise in sedentary lifestyles, significant consumption of unhealthy diets, and well-established clinical guidelines for managing cholesterol.

The hypercholesterolemia market size is projected to experience rapid expansion in the coming years. It is forecast to reach $35.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.8%. This growth during the forecast period can be linked to increasing awareness of familial hypercholesterolemia, a rise in the adoption of biologic therapies, the growing aging population, advancements in lipid profiling diagnostics, and the expansion of preventive healthcare initiatives. Significant trends expected in the forecast period include the increasing uptake of PCSK9 inhibitors, a heightened focus on early screening and diagnosis, a rising demand for combination lipid-lowering therapies, a shift towards injectable long-acting treatments, and the expanding role of preventive cardiovascular care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21207&type=smp

Which Core Factors Are Supporting The Expansion Of The Hypercholesterolemia Market?

The hypercholesterolemia market is anticipated to expand due to the rising incidence of cardiovascular diseases. These disorders, affecting the heart and blood vessels, are on the increase, attributed to factors such as unhealthy dietary habits, insufficient physical activity, a surge in obesity rates, ongoing stress, an aging global population, and the widespread occurrence of conditions like high blood pressure and diabetes. Treatment for hypercholesterolemia provides crucial support to individuals suffering from cardiovascular ailments by effectively reducing LDL cholesterol, diminishing arterial plaque accumulation, enhancing blood flow, and thereby lowering the likelihood of experiencing heart attacks, strokes, and other related complications. For example, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in October 2024, approximately 805,000 people in the United States suffer a heart attack annually; among these, 605,000 are initial events, while 200,000 affect those with a history of prior heart attacks. Consequently, the growing prevalence of cardiovascular diseases is projected to stimulate the expansion of the hypercholesterolemia market.

Which Segment Groups Define The Hypercholesterolemia Market Landscape?

The hypercholesterolemia market covered in this report is segmented –

1) By Disease Type: Genetic, Acquired

2) By Treatment: Statins, Bile Acid Resins, Niacin, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Other Treatments

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Home Healthcare, Other End Users

Subsegments:

1) By Genetic: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia

2) By Acquired: Primary Hypercholesterolemia, Secondary Hypercholesterolemia

What Trends Are Affecting The Growth Of The Hypercholesterolemia Market?

Leading firms within the hypercholesterolemia market are creating novel products, for instance, triple-combination drugs, aimed at boosting the effectiveness of treatment and improving patient adherence. A triple-combination drug is defined as a pharmaceutical preparation that merges three active components into one dosage unit, such as a tablet or a capsule. An example of this is the launch of Amrozet Tablet, a medication for hypertension and hyperlipidemia, by Celltrion Pharm, Inc., a pharmaceutical company based in South Korea, in February 2025. This particular drug integrates three active substances: amlodipine, a calcium channel blocker used for hypertension; rosuvastatin, a statin effective in decreasing cholesterol levels; and ezetimibe, which assists in diminishing cholesterol absorption within the intestines. It comes in four different dosage mixtures: 5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg. The medication is prescribed for hypertension and myocardial ischemia when considering amlodipine’s role, and for primary hypercholesterolemia through the rosuvastatin-ezetimibe combination. Furthermore, its applications include alleviating chronic stable angina (chest pain) or vasospastic angina, and reducing the likelihood of hospital admission for angina and cardiac surgery in individuals diagnosed with coronary artery disease.

Who Are The Companies Shaping The Hypercholesterolemia Market Landscape?

Major companies operating in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

Access The Complete Hypercholesterolemia Market Report:

https://www.thebusinessresearchcompany.com/report/hypercholesterolemia-global-market-report

Which Region Has The Strongest Presence In The Hypercholesterolemia Market?

North America was the largest region in the hypercholesterolemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypercholesterolemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Hypercholesterolemia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21207&type=smp

Browse Through More Reports Similar to the Global Hypercholesterolemia Market 2026, By The Business Research Company

Cholesterol Test Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholesterol-test-global-market-report

Low Density Lipoprotein Test Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/low-density-lipoprotein-test-global-market-report

Poc Cholesterol Test Market 2026

https://www.thebusinessresearchcompany.com/report/poc-cholesterol-test-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795